New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2014
06:01 EDTACORAcorda Therapeutics downgraded to Neutral from Buy at Citigroup
Citigroup downgraded Acorda Therapeutics citing a lack of near-term catalysts and lowered its price target for shares to $33 from $37.
News For ACOR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 24, 2015
07:09 EDTACORAcorda says oral levodopa reduces duration of OFF episodes in PD patients
Subscribe for More Information
June 16, 2015
07:05 EDTACORAcorda: Patients treated with CVT-301 showed greater motor function vs. placebo
Acorda Therapeutics presented data from a Phase 2b clinical trial of CVT-301, an inhaled levodopa under development for the episodic treatment of OFF episodes associated with Parkinsonís disease. OFF episodes are characterized by a re-emergence of PD motor symptoms, such as impaired ability to move, muscle stiffness and tremor. The trial showed that patients experiencing an OFF episode, treated with CVT-301, showed significantly greater improvements in motor function than patients treated with inhaled placebo; the difference in improvement was already apparent 10 minutes after dosing and was durable for at least an hour, the longest time point at which patients were measured. These data were presented at the 19th International Congress of Parkinson's Disease and Movement Disorders in San Diego, CA. The Phase 2b trial was a randomized, double blind, placebo-controlled, multicenter study in 86 people with PD for the treatment of OFF episodes. Participants were randomized to self-administer CVT-301 or placebo as an adjunct to oral PD medications. Participants received 35mg of CVT-301 or placebo delivered to the lung in weeks 1 and 2, and 50mg of drug or placebo delivered to the lung in weeks 3 and 4. In-office assessments of the Unified Parkinsonís Disease Rating Scale Part 3 were performed at weeks 1, 2 and 4. The primary endpoint was defined as the mean change from baseline in UPDRS III score after 4 weeks of treatment. UPDRS III is an established scale to monitor PD motor impairment, and is considered a standard in the field. In this study, participants receiving CVT-301 showed a statistically significant and clinically important reduction in average UPDRS III motor score compared to placebo and across all measured time points beginning at 10 and up to 60 minutes post-administration. Both doses of CVT-301 were well tolerated, with no increase relative to placebo in troublesome or non-troublesome dyskinesias during ON periods. There were no serious adverse events reported in the drug group, and the incidence of drug-related adverse events was similar between treatment groups. The most common adverse events were dizziness, headache and cough; there were no adverse events on cardiovascular or lung function. PD patients were able to self-administer treatment while in an OFF state.
June 15, 2015
09:19 EDTACORBiotech Industry Organization to hold a conference
BIO 2015 is being held in Philadelphia on June 15-18.
09:16 EDTACORInternational Parkinson & Movement Disorder Society to hold a conference
9th International Congress of Parkinson's Disease and Movement Disorders is being held in San Diego, CA on June 14-18.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use